Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

103.12 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
96 97 Next >
This Beaten-Down Growth Stock Has 99% Upside, According to Wall Street
A big turnaround could be in the cards for this medical device maker. 
Via The Motley Fool
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and... 
Via Talk Markets
Does Moderna's Cancer Breakthrough Make It a Good Stock to Buy Now?
Cancer vaccines have been around a long time, but they usually don't produce such compelling results. 
Via The Motley Fool
These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?
Today's big decliner could become tomorrow's market winner. 
Via The Motley Fool
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer
From Merck & Co., Inc.
Via Business Wire
This Is What Whales Are Betting On Merck & Co
Via Benzinga
The 3 Best Defensive Stocks to Buy in June 2023
With market and economic concerns rising, investors may find comfort targeting these ideas for the best defensive stocks to buy. 
Via InvestorPlace
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
Merck & Co Inc (NYSE: MRK) has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act (IRA).  
Via Benzinga
Novocure's Cancer Treating Electric Fields Improves Survival In Lung Cancer Patients, But Stock Tumbles On Remaining Doubts
Via Benzinga
Merck Delivers First Legal Blow To Biden's Medicare Negotiation Plan, Calling It A 'Sham'
The company hopes to block elements of the Inflation Reduction Act focused on the prices Medicare pays for drugs. 
Via Investor's Business Daily
U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients
From Merck & Co., Inc.
Via Business Wire
Analyst Ratings for Merck & Co
Via Benzinga
Why PDS Biotech Shares Are Jumping Today
Via Benzinga
Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%
Via Benzinga
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
Via ACCESSWIRE
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
From Merck & Co., Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
From Merck & Co., Inc.
Via Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
BioNTech is testing out a next-generation form of Yervoy, hoping to reduce side effects. 
Via Investor's Business Daily
3 Undervalued Dow Stocks to Buy Before Wall Street Does
The Street is down on the blue-chip index, but these undervalued Dow Jones stocks should generate big profits for long-term investors. 
Via InvestorPlace
Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Anastasia Amoroso of JPMorgan Private Bank named iShares 7-10 Year Treasury Bond ETF (NASDAQ: IEF) 
Via Benzinga
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
From Merck & Co., Inc.
Via Business Wire
7 Dividend Stocks to Buy (and Never Sell)
Each representing high-quality at reasonable prices, consider each of these seven some of the best long-term dividend stocks to buy. 
Via InvestorPlace
3 Innovative Growth Stocks to Buy for Next-Gen Profits
These are the innovative growth stocks for future profits as they represent companies investing significantly in research and development. 
Via InvestorPlace
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
Nvidia Becomes Ninth Company To Hit $1 Trillion Market Cap — Who Could Be Next To Join Elusive Club?
A surge in price for shares of Nvidia Corporation (NASDAQ: NVDA) after the company’s quarterly earnings results and guidance has put the semiconductor company in the elusive $1 trillion market... 
Via Benzinga
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin 
Via MarketBeat
Topics Death
Exposures Death Product Safety
Want to Grow Richer? These Stocks Have Doubled in the Past 5 Years
These two pharmaceutical companies have created value for shareholders. 
Via The Motley Fool
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class
Roche tested its treatment in patients with liver cancer and found "meaningful" results. 
Via Investor's Business Daily
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
96 97 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.